Press Release

India Monoclonal Antibodies Market to grow with a CAGR of 10.25%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the India Monoclonal Antibodies Market.


According to TechSci Research report, “India Monoclonal Antibodies Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, India Monoclonal Antibodies Market has valued at is anticipated to witness an impressive growth in the forecast period with a CAGR of 10.25 % through 2029.  This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

Innovation in research plays a significant role in driving the demand for Monoclonal Antibodies (mAbs). Ongoing research leads to the identification of new therapeutic targets. These targets may be specific proteins, antigens, or cells associated with diseases. When new targets are discovered, researchers often explore mAbs to develop precise and effective therapies. Research drives the development of novel mAbs. Scientists continually work on creating mAbs with improved specificity, efficacy, and safety profiles. This innovation results in a broader range of treatment options for various diseases. Research into personalized medicine and genetic variations in patient populations can identify individuals who are more likely to respond to specific mAbs. Tailoring mAb treatments to a patient's unique genetic and molecular profile is a growing area of research and innovation. Research explores the potential of combining mAbs with other treatments, such as chemotherapy, radiation therapy, or other targeted therapies. These combination therapies can enhance treatment outcomes and reduce side effects. In some cases, diseases, particularly cancers, develop resistance to existing therapies. Ongoing research aims to develop mAbs that can overcome this resistance and offer new options for patients.


Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " India Monoclonal Antibodies Market


In June 2021, Casirivimab and Indevimab are monoclonal antibodies designed to target the spike protein of SARS-CoV-2, the virus responsible for COVID-19. These antibodies have been made available in India and are specifically engineered to block the virus from attaching to and entering human cells. This advanced treatment offers protection to individuals who have tested positive for COVID-19 and are experiencing mild to moderate symptoms, with the goal of preventing their condition from worsening or necessitating hospitalization. This single-dose infusion-based therapy can be administered either intravenously or subcutaneously in a hospital's outpatient setting. After receiving the antibody infusion, patients are closely monitored for potential side effects for a few hours. Following this observation period, patients are allowed to return home for quarantine and are advised to diligently adhere to COVID-19 isolation protocols.

Safety and monitoring are critical challenges in the India Monoclonal Antibodies (mAbs) Market, as they are in any healthcare sector. Ensuring the safety of patients receiving mAb therapies and monitoring their outcomes is of paramount importance. One of the key safety concerns with mAbs is the potential for patients to develop immune responses to the therapy. This immune reaction can affect the mAb's efficacy and safety. Monitoring immunogenicity and developing strategies to mitigate its impact are essential. Like any medical treatment, mAb therapies can lead to adverse events or side effects. Monitoring and reporting of adverse events are crucial for patient safety and for gathering data on the safety profile of mAbs. Some mAbs are administered intravenously, and patients may experience infusion-related reactions, which can range from mild to severe. Proper monitoring during and after infusion is necessary to manage these reactions. As mAb treatments may be administered over an extended period, it's essential to monitor and assess their long-term safety and any potential cumulative effects. Ensuring that patients adhere to their prescribed mAb treatment regimens and monitoring their compliance is crucial for both safety and treatment effectiveness. Individual patient responses to mAbs can vary. Optimizing the dose and treatment regimen for each patient is important for safety and efficacy.

India Monoclonal Antibodies Market is segmented based on Type, Application, Production, Biomanufacturing, End-user, and by region.

Based on the Application, India Monoclonal Antibodies Market is segmented into Cancer, Cardiac/Cardiovascular, Neurological, Others. Neurological disorders encompass a wide range of conditions affecting the nervous system, including the brain and spinal cord. These disorders can be neurodegenerative diseases (e.g., Alzheimer's and Parkinson's), autoimmune disorders (e.g., multiple sclerosis), or conditions like stroke and neuromuscular disorders. Some neurological disorders are caused by the immune system mistakenly attacking components of the nervous system. Monoclonal antibodies can be designed to target and modulate specific immune responses responsible for these autoimmune neurological disorders. Multiple sclerosis (MS) is a common autoimmune neurological disorder. Certain mAbs have been developed to modulate the immune response in MS by targeting specific immune cells or molecules responsible for the inflammatory and demyelinating processes in the central nervous system. Neurodegenerative diseases like Alzheimer's and Parkinson's are characterized by the accumulation of abnormal proteins or protein aggregates in the brain. Monoclonal antibodies are being researched as potential treatments to target and clear these pathogenic proteins or to modulate the inflammatory responses associated with these diseases.

Based on Region, North India held the largest share in the India Monoclonal Antibodies Market. The availability of venture capital, private equity, and funding opportunities in the North Indian region attracts both startups and established companies to invest in monoclonal antibody research and development. North India often serves as a preferred location for clinical trials due to its diverse patient population, which is essential for testing the safety and efficacy of mAb therapies. The region's strong network of academic institutions, research centers, and pharmaceutical companies encourages collaborations and partnerships, accelerating the advancement of mAb-related projects. The North Indian region, with its large and diverse population, has a high demand for advanced medical treatments, including mAbs. This demand drives the development and commercialization of these therapies. The region's connectivity, proximity to major ports, and transportation infrastructure make it favorable for the import of critical raw materials and the export of finished mAb products.


Some of the major companies operating in the India Monoclonal Antibodies Market include:

  • Dr. Reddy's Laboratories Ltd.
  • Bristol Myers Squibb India Pvt. Ltd.
  • Roche India Pvt. Ltd.
  • Intas Pharmaceuticals Limited
  • Merck India
  • Eli Lilly, and Company (India) Private Limited
  • Biocon Limited
  • AstraZeneca India Pvt. Ltd.
  • Pfizer Limited


Download Free Sample Report

Customers can also request 10% free customization on this report


“Certain areas, particularly in North America, are projected to exert significant demand for Monoclonal Antibodies. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the India Monoclonal Antibodies Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

India Monoclonal Antibodies Market by Type (Murine, Chimeric, Humanized, Human), By Application (Cancer, Cardiac/Cardiovascular, Neurological, Others), By Production (In vitro, In vivo), By Biomanufacturing (Originator, CMO), By End Users (Hospitals, Research Laboratories, Others), By Region, By Competition Forecast & Opportunities, 2019-2029F has evaluated the future growth potential of India Monoclonal Antibodies Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in India Monoclonal Antibodies Market.


Contact Us-

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

M: +13322586602

Email: [email protected]


Relevant News